FWM
RVNC

Fairhaven Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fairhaven Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,859
Closed -$38.2K – 129
2024
Q2 		$38.2K Hold
14,859
– – 0.01% 119
2024
Q1 		$73.1K Hold
14,859
– – 0.03% 122
2023
Q4 		$131K Buy
+14,859
New +$122K 0.05% 109

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Fairhaven Wealth Management's RVNC Position: Q3 2024 in Review

Fairhaven Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 14,859 shares — an estimated $38.2K sold.

Fairhaven Wealth Management first reported a position in RVNC in Q4 2023 and held it in 3 quarters. The position peaked at $131K in Q4 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Fairhaven Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Fairhaven Wealth Management sold 14,859 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $38.2K.
  • Fairhaven Wealth Management first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 3 quarters.
  • Fairhaven Wealth Management's Revance Therapeutics, Inc. position peaked at $131K in Q4 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Fairhaven Wealth Management's 13F filing for Q3 2024, filed 12 Nov 2024.